Romiplostim plus steroids for newly diagnosed ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with primary ITP within the last 3 months.
- You have not received any ITP treatments before.
- Your platelet count is below 30,000 per microliter.
- You are in generally good health (able to carry out daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two medicines—one that calms the immune system and one that helps your body make more platelets. It is for people with long-term ITP who have already tried other treatments and still have low platelet counts.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
This study tests a sequence of two medicines that help raise platelet counts in people with severe ITP. The first is given as an injection, and the second is a pill, and they are given after standard steroid treatment. The goal is to see if this approach can improve platelet levels safely.
This study tests a new combination of two medicines (ianalumab and eltrombopag) for children with a blood condition called ITP (low platelets causing bruising and bleeding) who haven't improved with steroids. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.